image sourced from original article at Hetero has begun exporting its generic semaglutide injection portfolio to more than 75 countries as part of a multi-year plan to expand access to treatments for type 2 diabetes and obesity. Initial rollouts are under way across Africa, Asia and the Middle East, with further launches planned in additional markets subject to regulatory approvals.
The injectable therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G. The products are available in multi-dose disposable pen devices designed in line with innovator formats and offered in strengths ranging from 0.25 mg to 2.4 mg, providing flexible dosing options for both diabetes and obesity care.
The company said the initiative supports its broader strategy to improve access to advanced cardio-metabolic treatments, particularly in emerging markets. Hetero is also awaiting regulatory clearance in India following the completion of clinical trials and plans to launch the product domestically after approval, leveraging its global manufacturing and commercial network spanning more than 145 countries.
